KAB86952
Colorimetric
Plasma, Serum
Quantitative
15.625-1,000 ng/ml
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Fab C225,IMC-225,cetuximab-IR700, CAS: 205923-56-4
Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibody., PMID:38309099
Bioluminescence Goes Dark: Boosting the Performance of Bioluminescent Sensor Proteins Using Complementation Inhibitors., PMID:36450135
Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro., PMID:35482455
Dual inhibition of RNAi therapeutic miR-26a-5p targeting cMet and immunotherapy against EGFR in endometrial cancer treatment., PMID:33553298
Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3., PMID:32430487
Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells., PMID:32382339
Human Immunodeficiency Virus-Associated Exosomes Promote Kaposi's Sarcoma-Associated Herpesvirus Infection via the Epidermal Growth Factor Receptor., PMID:32051269
CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer., PMID:31815051
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study., PMID:31648099
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial., PMID:31126331
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma., PMID:30890189
Anti-vasospastic Effects of Epidermal Growth Factor Receptor Inhibitors After Subarachnoid Hemorrhage in Mice., PMID:30382533
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study., PMID:30327312
Role of epidermal growth factor receptor in lung cancer and targeted therapies., PMID:28337370
Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer., PMID:28320945
The role of RNase 7 in innate cutaneous defense against Pseudomonas aeruginosa., PMID:27513608
Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies., PMID:27399333
Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor., PMID:26269754
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells., PMID:25474137
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy., PMID:25344208
KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells., PMID:24136682
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2., PMID:23948973
Promotion of neuronal differentiation of neural progenitor cells by using EGFR antibody functionalized collagen scaffolds for spinal cord injury repair., PMID:23591390
A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF., PMID:23251664
Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer., PMID:22089117
A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death., PMID:21915281
Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors., PMID:21051930
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan., PMID:20666740
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent., PMID:19276250
Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer., PMID:19257852
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers., PMID:17913857
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells., PMID:15887238
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
